(NASDAQ: VERU) Veru's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.
Veru's earnings in 2026 is -$19,113,511.On average, 4 Wall Street analysts forecast VERU's earnings for 2026 to be -$19,400,022, with the lowest VERU earnings forecast at -$22,492,918, and the highest VERU earnings forecast at -$15,841,666. On average, 4 Wall Street analysts forecast VERU's earnings for 2027 to be -$19,645,592, with the lowest VERU earnings forecast at -$19,661,642, and the highest VERU earnings forecast at -$19,380,761.
In 2028, VERU is forecast to generate -$13,178,918 in earnings, with the lowest earnings forecast at -$17,459,538 and the highest earnings forecast at -$8,426,418.